Please assess the completion status of the following clinical trial:

Trial Title: [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 18 years of age~* Subjects must have signed and dated an informed consent prior to any study-specific procedures~* Subjects with histologically-confirmed tumor for whom a recent biopsy (not older than 6-months old) has been performed.~* Dosimetry group: luminal breast cancer, adenocarcinoma of the prostate~* Non-dosimetry group: luminal breast cancer, adenocarcinoma of the prostate, small cell lung cancer, non-small cell lung cancer, colorectal carcinoma~* At least one malignant lesion detected via functional or morphological imaging (PET combined to appropriate tracer according to tumor type, CT, MRI) within 3 months prior to \[68Ga\]-NeoBOMB1 administration~* The Eastern Cooperative Oncology (ECOG) performance status 0-2.~* Subjects must agree to use highly effective methods of contraception (female partners of male participants should use highly effective methods of contraception) during the trial.~Exclusion Criteria:~* renal insufficiency or an eGFR \<50 ml/min/1.73m2~* hematological toxicity grade \> 2 (Toxicity Grading Scale in vaccine clinical trials)~* participation in any other investigational trial within 30 days of study entry~* subjects with positive pregnancy test (urine dipstick), and/or currently breast-feeding~* concurrent severe illness or clinically relevant trauma within 2 weeks before the administration of the investigational product that might preclude study completion or interfere with study results~* concurrent bladder outflow obstruction or unmanageable urinary incontinence~* known or expected hypersensitivity to \[68Ga\]-NeoBOMB1 or any excipient present in \[68Ga\]-NeoBOMB1~* any condition that precludes raised arms position~* prior administration of a radiopharmaceutical within a period corresponding to 8 half-lives of the radionuclide~* history of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase II dosimetry group (Type: EXPERIMENTAL): All eligible participants were to receive recommended dose of \[68Ga\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\].
- Phase II non-dosimetry group (Type: EXPERIMENTAL): All eligible participants were to receive recommended dose of \[68Ga\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\].

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues